Weiss Ratings Reaffirms "Sell (D-)" Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Key Points

• Weiss Ratings has restated its "Sell (D-)" rating for Dianthus Therapeutics (NASDAQ:DNTH), highlighting ongoing concerns regarding the firm's financial performance.
• Despite the negative rating from Weiss, several research firms, including William Blair and Wedbush, have issued "outperform" and "buy" ratings, reflecting a divided sentiment among analysts.
• Dianthus Therapeutics reported a significant earnings miss with an EPS of ($0.88), falling short of the consensus estimate of ($0.86), indicating challenges in revenue generation.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report)'s stock had its "sell (d-)" rating restated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other research firms also recently commented on DNTH. William Blair initiated coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating for the company. Wedbush increased their target price on Dianthus Therapeutics from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Friday, September 12th. Stifel Nicolaus increased their target price on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Guggenheim increased their target price on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, September 9th. Finally, Robert W. Baird increased their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an "outperform" rating in a research note on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $61.57.

Dianthus Therapeutics Price Performance

Shares of DNTH stock traded up $0.05 on Wednesday, hitting $34.75. 772,947 shares of the company's stock were exchanged, compared to its average volume of 859,102. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $40.16. The stock has a market cap of $1.12 billion, a P/E ratio of -10.69 and a beta of 1.58. The company has a 50 day moving average of $28.99 and a 200 day moving average of $22.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Sell-side analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.15% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNTH. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $27,000. US Bancorp DE lifted its holdings in shares of Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after purchasing an additional 1,510 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after buying an additional 3,317 shares during the last quarter. Finally, AlphaQuest LLC purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $94,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.